The content on this site is intended for healthcare professionals only
At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Suzanne Topalian presented results from an early-stage study showing treatment with the investigational drug BMS-936558.
The drug caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and non-small cell lung (NSCLC) cancers.
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Highlights and analysis
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Psychological issues in familial cancer
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
ASCO 2024: Lung cancer highlights
